ClinicalTrialsFinder

Harbour Cancer & Wellness ( Site 5600)

Newmarket, Auckland, New Zealand

1 recruiting

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled250 locationsNCT06841354